Structure, function, and pharmacology of glutamate receptor ion channels

KB Hansen, LP Wollmuth, D Bowie, H Furukawa… - Pharmacological …, 2021‏ - Elsevier
Many physiologic effects of l-glutamate, the major excitatory neurotransmitter in the
mammalian central nervous system, are mediated via signaling by ionotropic glutamate …

Mechanisms of ketamine and its metabolites as antidepressants

EM Hess, LM Riggs, M Michaelides… - Biochemical pharmacology, 2022‏ - Elsevier
Treating major depression is a medical need that remains unmet by monoaminergic
therapeutic strategies that commonly fail to achieve symptom remission. A breakthrough in …

Experimenters' sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor

P Georgiou, P Zanos, TCM Mou, X An… - Nature …, 2022‏ - nature.com
We show that the sex of human experimenters affects mouse behaviors and responses
following administration of the rapid-acting antidepressant ketamine and its bioactive …

Psychedelics and neural plasticity: therapeutic implications

SF Grieco, E Castrén, GM Knudsen, AC Kwan… - Journal of …, 2022‏ - jneurosci.org
Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural
attitudes toward them are changing, and scientists are once again investigating the neural …

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial

P Glue, C Loo, J Fam, HY Lane, AH Young… - Nature medicine, 2024‏ - nature.com
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major
depression (TRD). The safety and tolerability of racemic ketamine may be improved if given …

Nanomedomics

G Liang, W Cao, D Tang, H Zhang, Y Yu, J Ding… - ACS …, 2024‏ - ACS Publications
Nanomaterials have attractive physicochemical properties. A variety of nanomaterials such
as inorganic, lipid, polymers, and protein nanoparticles have been widely developed for …

The molecular pathophysiology of depression and the new therapeutics

H Tian, Z Hu, J Xu, C Wang - MedComm, 2022‏ - Wiley Online Library
Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the
many hypotheses proposed to understand the molecular pathophysiology of depression, it is …

The abuse liability of ketamine: A sco** review of preclinical and clinical studies

TT Le, IP Cordero, MY Jawad, J Swainson… - Journal of psychiatric …, 2022‏ - Elsevier
While ketamine has been used clinically over the past decades, it has only been recently
shown to be a promising therapy for treatment-resistant depression (TRD). However …

Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis

GC Medeiros, TD Gould, WL Prueitt, J Nanavati… - Molecular …, 2022‏ - nature.com
Abstract (R, S)-ketamine (ketamine) and its enantiomer (S)-ketamine (esketamine) can
produce rapid and substantial antidepressant effects. However, individual response to …

Narrative review: low-dose ketamine for Pain Management

A Riccardi, M Guarino, S Serra… - Journal of Clinical …, 2023‏ - mdpi.com
Pain is the leading cause of medical consultations and occurs in 50–70% of emergency
department visits. To date, several drugs have been used to manage pain. The clinical use …